[ad_1]
Lisbon, Portugal – March 15, 2019: The discovery of subtypes of atrial fibrillation paves the way for individualized treatment. This is the main message of the EHRA / AFNET Joint Conference, which will present the new data from the CATCH ME project and leads to a consensus on personalized medicine approaches to improve patient care.1
The meeting will be held on March 15 and 16 in Lisbon, Portugal. It is organized by the European Heart Association (EHRA) of the European Society of Cardiology (ESC) and the atrial fibrillation network (AFNET) with funding from the EU Horizon 2020 grant from the CATCH ME consortium.
Atrial fibrillation is the most common heart rhythm disorder (arrhythmia). It is causing 20 to 30% of strokes and also increases the risk of heart failure and sudden death.2 The signs of atrial fibrillation include palpitations, shortness of breath, fatigue, chest pain and vertigo.3
Professor Paulus Kirchhof, one of the organizers of the event and chair of the 2016 ESC guidelines on atrial fibrillation, said: "Atrial fibrillation remains one of the conditions the most common and challenging in cardiology Patients have different profiles and medical issues related to atrial fibrillation.At the meeting, we will review emerging data to discover patient profiles for precision medicine, which will allow clinicians and researchers to better estimate who will benefit from current and emerging therapies. "
The new CATCH ME project results help define the clinical types of atrial fibrillation based on the main cause and help to better understand the mechanisms of atrial fibrillation derived from the badysis of atrial tissue gene expression. humans. The results of these studies will be presented in full at the EHRA 2019 Congress. 4 New information will also be presented on blood biomarkers for different types of atrial fibrillation, as well as on outcomes in patients with atrial fibrillation also suffering from heart failure. in those with heart failure. who have bleeding.
About 80 leading scientists and clinicians in atrial fibrillation management and research, as well as industry partners, will participate in the conference. It will cover the entire spectrum of atrial fibrillation, from gene expression patterns in ear tissues (the "molecular signature") to clinical types, including patient management, health systems, and the education of patients. patients. This scale will be reflected in a consensus document. Among the statements that will be agreed upon are how to adapt the use of anticoagulation therapy and rhythm rhythm therapy to newly defined types of atrial fibrillation.
The title of the meeting is "Management of Atrial Fibrillation Patients: New Therapies and Special Populations". In addition to populations revealed by CATCH ME, these include patients with:
- Bleeding under anticoagulation, for which a shutter of the left atrial appendage can prevent stroke with a lower bleeding risk
- Concomitant cardiac insufficiency, for which there is controversy over the benefits of rhythm control therapy, particularly catheter ablation
- End-stage renal disease presenting a high risk of stroke and bleeding
- Very rare atrial arrhythmias detected by devices, including smartwatches.
The current status of applications (applications) for the diagnosis and management of atrial fibrillation will be presented, as well as up-to-date knowledge on how atrial fibrillation contributes to cognitive dysfunction and dementia as a result of the diagnosis of atrial fibrillation. an EHRA consensus document released last year. .6
Professor Hein Heidbuchel, chairman of EDHP, one of the organizers of the event, said: "It takes a more personalized medicine for the diverse group of patients with atrial fibrillation. science advances quickly and at this meeting, world experts will gather for data to refine the diagnosis and treatment of patients with atrial fibrillation Our goal is to better control symptoms and further reduce risk of stroke and premature death of affected patients. "
###
Authors: ESC Press Office
+33 (0) 4 8987 2499
Email: [email protected]
Follow us on twitter @ESCardioNews
The hashtag for the EHRA 2019 Congress is # ehra2019.
Funding sources: The characterization of atrial fibrillation by translating its causes into health modifiers in the elderly (CATCH ME), grant 633196 from the EU Horizon 2020 Consortium.
Disclosures: None.
References and notes
1The 7th EHRA / AFNET Consensus Conference, "Management of Atrial Fibrillation Patients: New Treatments and Special Populations," will be held in Lisbon, Portugal on March 15 and 16, 2019.
2Kirchhof P, Benussi S, Kotecha D, et al. The 2016 ESC guidelines for the management of atrial fibrillation have been developed in collaboration with EACTS. Eur Heart J. 2016; 37: 2893-2962. doi: 10.1093 / eurheartj / ehw210.
3How to recognize the signs and symptoms of atrial fibrillation: https: /
4L "Abstract" Development of a prognostic model for recurrent atrial fibrillation with the help of individual data from 2429 patients with AF: preliminary results of the CATCH ME study "will be presented at Congress Session EHRA 2019 Moderate ePosters 10: Clinical AF on Monday, March 18th at 3:35 pm to 4:25 pm WET (GMT) in the poster area.
5L "Abbreviated" Specific Lateral Differences in Atrial Tissue Expression is Associated with Atrial Fibrillation and Heart Failure: The CATCH ME Consortium "Will Be Presented at the EHRA 2019 Congress Session: ePosters moderate 9: new basic presentation on arrhythmia in the world, Monday, March 18 at 10:05 to 10:55 WET (GMT) in the poster area.
6Dagres N, TF Chao, Fenelon G, et al. European Heart Rhythm Association (EHRA) / Heart Rhythm Society (HRS) / Asia-Pacific Heart Rhythm Society (APHRS) / Latin American Heart Rhythm Association (LAHRS) on arrhythmias and cognitive function: is the best practice? Europace. 2018; 20: 1399-1421. doi: 10.1093 / europace / euy046.
About the European Heart Rhythm Association
The European Heart Rhythm Association (EHRA) is a branch of the European Society of Cardiology (ESC). Its goal is to improve the quality of life and reduce sudden cardiac death by limiting the impact of cardiac arrhythmias. EHRA disseminates knowledge and sets standards; offers continuing education, training and certification to physicians and related professionals involved in the field of cardiac arrhythmias, with a focus on atrial fibrillation (AF) and electrophysiology (EP). EHRA publishes consensus documents and international positions. It is a source of high quality, unbiased, evidence-based scientific information that promotes the quality of care for AF patients, and has also dedicated a website. for the benefit of patients "afibmatters.org". . #EHRA
About the EHRA congress
EHRA 2019 is the annual congress of the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
About the European Society of Cardiology
The European Society of Cardiology brings together health professionals from more than 150 countries who are working to advance cardiovascular medicine and help people live longer and healthier lives.
Information for journalists present at EHRA 2019
EHRA 2019 will be held from 17 to 19 March at the Lisbon Congress Center (CCL) in Lisbon, Portugal. Explore the scientific program.
- To register on-site, please bring a valid press card or an appropriate engagement letter, with proof of three recently published articles (cardiology or health related, or making reference to a previous ESC event).
- Press registration is not available to the industry or its public relations, event management, marketing, or communications representatives.
Warning: AAAS and EurekAlert! are not responsible for the accuracy of the news releases published on EurekAlert! contributing institutions or for the use of any information via the EurekAlert system.
[ad_2]
Source link
